Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2a study of NXN-188 for acute treatment of migraine attacks with aura
2009-010721-39Phase 2Completed
- Sponsor
- Peer Tfelt-Hansen
- Start
- Mar 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, single-arm trial of NXN-188 in migraine with aura, sponsored by Peer Tfelt-Hansen. Primary endpoints: Headache intensity at 2 hours after dosing and Number of pain-free subjects 2 hours after dosing. Started Mar 2009; status: completed.
02
Drugs
NXN-188
03
Conditions
migraine with aura
Beyond the preview
Go deeper on 2009-010721-39.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-010721-39.